Trial Profile
A Randomized, Double-Blind, Controlled, Phase 2/3 Study to Assess Efficacy, Long Term Safety and Tolerability of RT001 in Subjects With Friedreich's Ataxia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 15 Mar 2023
Price :
$35
*
At a glance
- Drugs RT 001 (Primary)
- Indications Friedreich's ataxia
- Focus Registrational; Therapeutic Use
- Sponsors Retrotope
- 01 Mar 2023 Primary endpoint has not been met. (Change From Baseline to 11 Months in Maximum Consumption of Oxygen (mlO2/kg/Min) Using Cardiopulmonary Exercise Testing (CPET)) according to results published in Journal of Neurology.
- 01 Mar 2023 Results published in the Journal of Neurology
- 04 May 2022 Status changed from active, no longer recruiting to completed.